PharmAthene was formed to address the urgent biosecurity needs of this Nation and its Allies. Since the terrorist attacks in 2001 and the subsequent deliberate anthrax exposure to the U.S. population, the vulnerability of this Nation to a wide array of threats has come into sharp focus. Additionally, the Nation has recognized how woefully unprepared it is for future attacks. The U.S. Government has responded by allocating a significant amount of funding to develop technologies and products to address threats through development of the Department of Homeland Security and unprecedented funding for the biodefense market through the recently enacted Project BioShield Law. As a Company founded on the principle of developing a comprehensive array of countermeasures to biological and chemical terrorism, PharmAthene has demonstrated its ability to achieve its mission of being the leading developer and provider of countermeasures to potential bioweapons and is well positioned to be meet the urgent needs of the U.S. Government under the Project BioShield legislation.
PharmAthene is engaged in the discovery and development of new human therapeutics and prophylactics for the treatment and prevention of morbidity and mortality from exposure to chemical and biological weapons. PharmAthene's mission is to seize leadership in this emerging area by developing a portfolio of products urgently needed by the U.S. Government and its Allies. PharmAthene has two products under development that are intended to provide protection from anthrax and chemical threats. Beyond its initial focus in biodefense, PharmAthene intends to identify and develop dual-use technologies which have applications and indications in broader commercial markets.